行情

IMMU

IMMU

Immunomedics
NASDAQ

实时行情|Nasdaq Last Sale

44.41
+2.18
+5.16%
盘后: 44.84 +0.43 +0.97% 17:53 08/03 EDT
开盘
42.86
昨收
42.23
最高
44.84
最低
42.51
成交量
266.59万
成交额
--
52周最高
44.84
52周最低
8.80
市值
102.54亿
市盈率(TTM)
-24.3690
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测IMMU价格均价为48.96,最高价位56.00,最低价为32.00。

EPS

IMMU 新闻

更多
Immunomedicals shares are trading higher after B of A Securities maintained a Buy rating on the company's stock and raised its price target from $45 to $47.
Benzinga · 5小时前
2 “Strong Buy” Healthcare Stocks That Could Be the Next M&A Target
Which stocks have been the stars of 2020? Biotechs. Amid the onset of the global health crisis, companies advancing COVID-19 vaccines, treatments and testing kits have seen their shares take off rapidly on an upward trajectory. That said, Wall Street focus has
TipRanks · 5天前
Biotech Bonanza - Second Half Outlook
Seeking Alpha · 6天前
4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront
MotleyFool.com · 6天前
AstraZeneca Inks Multibillion-Dollar Cancer Treatment Collaboration
AstraZeneca on Monday unveiled a cancer treatment partnership with a Japanese company that could be worth as much as $6 billion and aims for best-in-class treatment of lung and other cancer.
Investor's Business Daily · 07/27 20:10
Immunomedics Analyst Says Trodelvy Likely To Capture 50% Market Share
Immunomedics, Inc. (NASDAQ: IMMU) stock, which has been on a broader upward trajectory since FDA approved its lead asset Trodelvy, has further room to run, according to a Jefferies analyst. The Immunomedics Analyst: Chris Howerton reiterated a Buy rating on I
Benzinga · 07/27 18:23
Immunomedics shares are trading higher after Jefferies Maintained its Buy rating on the stock and raised its price target from $41 to $55 per share.
Benzinga · 07/27 12:51
Immunomedics to Report Second Quarter 2020 Results and Host Conference Call and Webcast on August 5, 2020
MORRIS PLAINS, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that it will host a conference call on Wedn
GlobeNewswire · 07/27 12:00

所属板块

生物技术和医学研究
+3.60%
制药与医学研究
+2.08%

热门股票

代码
价格
涨跌幅

IMMU 简况

Immunomedics, Inc.是一家临床阶段生物制药公司。该公司致力于开发基于单克隆抗体用于癌症靶向治疗的产品。该公司技术使其能够产生人源化抗体,可单独以未标记或裸露形式使用,或与放射性同位素、化学治疗剂、细胞因子或毒素结合使用。该公司拥有六个临床阶段候选产品。其研究产品组合包括抗体偶联药物(ADC),用于将有效载荷的化学治疗剂直接递送至肿瘤并同时管理在常规施用化学治疗剂时产生的总体毒性作用。该公司的ADC包括sacituzumab govitecan(IMMU-132)和labetuzumab govitecan(IMMU-130)。该公司还拥有一系列处于临床和临床前开发阶段针对实体肿瘤、恶性血液病以及其他疾病的其他候选产品。
展开

微牛提供Immunomedics, Inc.(NASDAQ-IMMU)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的IMMU股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易IMMU股票基本功能。